Glutamatergic systems in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 18, Issue SUPPL. 1, 2003, Pages

  Francis, Paul T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acetylcholine; Alzheimer's disease; Cognitive dysfunction; Glutamate; Long term potentiation; Pyramidal neurones

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENYLATE CYCLASE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMINO ACID; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; KAINIC ACID; KAINIC ACID RECEPTOR; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROTRANSMITTER; PHOSPHOLIPASE C;

ALZHEIMER DISEASE; APOPTOSIS; BIOCHEMISTRY; BRAIN CORTEX; CELL DEATH; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; CYTOTOXICITY; ENZYME SYNTHESIS; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; LEARNING; MEMORY; NECROSIS; NEOCORTEX; NERVE CELL; NERVE CELL STIMULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; PYRAMIDAL NERVE CELL; SYNAPTIC TRANSMISSION;

AGED; ALZHEIMER DISEASE; CELL DEATH; COGNITION; GLUTAMIC ACID; HUMANS; PYRAMIDAL CELLS; SYNAPTIC TRANSMISSION;

EID: 0141483708     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.934     Document Type: Conference Paper

References (69)

1. Allen SJ, Wilcock GK, Dawbarn D. 1999. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem Biophys Res Commun 264: 648-651.
2. Anderson KJ, Bridges RJ, Cotman CW. 1991. Increased density of excitatory amino acid transport sites in the hippocampal formation following an entorhinal lesion. Brain Res 562: 285-290.
3. Armstrong DM, Ikonomovic MD. 1996. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal dentate gyrus of patients with Alzheimer disease. Evidence for hippocampal plasticity. Mol Chem Neuropathol 28: 59-64.
4. Baudry M, Lynch G. 2001. Remembrance of arguments past: How well is the glutamate receptor hypothesis of LTP holding up after 20 years? Neurobiol Learn Mem 76: 284-297.
5. Beal MF. 1998. Mitochondrial dysfunction in neurodegenerative diseases. Biochem Biophys Acta 1366: 211-223.
6. Beckstrom H, Julsrud L, Haugeto O, et al. 1999. Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. J Neurosci Res 55: 218-229.
7. Behl C. 1997. Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res 290: 471-480.
8. Bellocchio EE, Reimer RJ, Fremeau RT, Jr., Edwards RH. 2000. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 289: 957-960.
9. Bondolfi L, Calhoun M, Ermini F, et al. 2002. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 22: 515-522.
10. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropath 82: 239-259.
11. Bruno V, Battaglia G, Copani A, et al. 2001. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21: 1013-1033.
12. Chessell IP, Humphrey PPA. 1995. Nicotinic and muscarinic receptor-evoked depolarisations recorded from a novel cortical brain slice preparation. Neuropharmacol 34: 1289-1296.
13. Conn PJ, Pin JP. 1997. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
14. Cowburn R, Hardy JA, Roberts PJ, Briggs R. 1988. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett 86: 109-113.
15. Danbolt NC. 2001. Glutamate uptake. Prog Neurobiol 65: 1-105.
16. +-Dependent 'binding' of D-aspartate in brain membranes is largely due to uptake into membrane-bounded saccules. J Neurochem 47: 819-824.
17. DeKosky ST, Scheff SW. 1990. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27: 457-464.
18. Dijk SN, Francis PT, Stratmann GC, Bowen DM. 1995. Cholinomimetics increase glutamate outflow by an action on the corticostriatal pathway: Implications for Alzheimer's disease. J Neurochem 65: 2165-2169.
19. Esiri M. 1991. Neuropathology. In Psychiatry in the Elderly, Jacoby, Oppenheimer (eds). Oxford University Press: Oxford, UK; 113-147.
20. Ferrarese C, Aliprandi A, Tremolizzo L, et al 2001. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 57: 671-675.
21. Fonnum F. 1984. Glutamate: A neurotransmitter in mammalian brain. J Neurochem 42: 1-11.
22. Francis PT, Palmer AM, Snape M, Wilcock GK. 1999. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 66: 137-147.
23. Francis PT, Sims NR, Procter AW, Bowen DM. 1993. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspectives. J Neurochem 60: 1589-1604.
24. Gadea A, Lopez-Colome AM. 2001. Glial transporters for glutamate, glycine and GABA I. Glutamate transporters. J Neurosci Res 63: 453-460.
25. Geula C, Mesulam MM. 1999. Cholinergic systems in Alzheimer's disease. In Alzheimer's Disease (2nd ed), Terry, Katzman, Bick, Sisodia (eds). Lippincott Williams and Wilkins: Philadelphia, USA; 269-292.
26. Giulian D. 1999. Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet 65: 13-18.
27. Gomez-Isla T, Hollister R, West H, et al. 1997. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41: 17-24.
28. Greenamyre JT, Maragos WF. 1993. Neurotransmitter receptors in Alzheimer-disease. Cereb Brain Metabol Rev 5: 61-94.
29. Greenamyre JT, Young AB. 1989. Excitatory amino acids in Alzheimer's disease. Neurobiol Aging 10: 593-602.
30. Hyman BT, Van Hoesen GW, Damasio AR. 1987. Alzheimer's disease: Glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 22: 37-40.
31. Ikonomovic MD, Armstrong DM. 1996. Distribution of AMPA receptor subunits in the nucleus basalis of Meynert in aged humans: Implications for selective neuronal degeneration. Brain Res 716: 229-232.
32. Irizarry MC, Soriano F, McNamara M, et al. 1997. A beta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17: 7053-7059.
33. Jay TM, Zilkha E, Obrenovitch TP. 1999. Long-term potentiation in the dentate gyrus is not linked to increased extracellular glutamate concentration. J Neurophysiol 81: 1741-1748.
34. Keller JN, Mark RJ, Bruce AJ, et al. 1997. 4-hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 80: 685-696.
35. Korey SR, Scheinberg L, Terry R, Stein A. 1961. Studies in presenile dementia. Trans Am Neurol Assoc 86: 99-102.
36. Kowall NW, Beal MF. 1991. Glutamate-, glutaminase-, and taurine-immunoreactive neurones develop neurofibrillary tangles in Alzheimer's disease. Ann Neurol 29: 162-167.
37. Lewis DA, Campbell MJ, Terry RD, Morrison JH. 1987. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease a quantitative study of visual and auditory cortices. J Neurosci 7: 1799-1809.
38. Li S, Mallory M, Alford M, Tanaka S, Masliah E. 1997. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56: 901-911.
39. Lipton P. 1999. Ischemic cell death in brain neurons. Physiol Rev 79: 1431-1568.
40. Lowe SL, Bowen DM, Francis PT, Neary D. 1990. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 38: 571-577.
41. Lynch G. 1998. Memory and the brain: Unexpected chemistries and a new pharmacology. Neurobiol Learn Mem 70: 82-100.
42. Maragos WF, Greenamyre JT, Penney JB, Young AB. 1987. Glutamate dysfunction in Alzheimer's disease: An hypothesis. Trends Neurosci 10: 65-68.
43. Mattson MP. 2000. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1: 120-129.
44. Meldrum BS, Chapman AG. 1999. Excitatory amino acid receptors and antiepileptic drug development. Adv Neurol 79: 965-978.
45. Meldrum BS, Garthwaite J. 1990. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11: 993-996.
46. Morrison JH, Hof PR. 1997. Life and death of neurons in the aging brain. Science 278: 412-419.
47. Mudher A, Lovestone S. 2002. Alzheimer's disease - Do tauists and baptists finally shake hands? Trends Neurosci 25: 22-26.
48. Myhrer T. 2000. Effects of selective perirhinal and postrhinal lesions on acquisition and retention of a visual discrimination task in rats. Neurobiol Learn Mem 73: 68-78.
49. Najlerahim A, Bowen DM. 1988. Regional weight loss of the cerebral cortex and some subcortical nuclei in senile dementia of the Alzheimer type. Acta Neuropath 75: 509-512.
50. Neary D, Snowden JS, Mann DM, et al. 1986. Alzheimer's disease: A correlative study. J Neurol Neurosurg Psychiatry 49: 229-237.
51. Obrenovitch TP, Urenjak J, Zilkha E, Jay TM. 2000. Excitotoxicity in neurological disorders - The glutamate paradox. Int J Dev Neurosci 18: 281-287.
52. Olney JW, Ho OL, Rhea V. 1971. Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse nervous system. Exp Brain Res 14: 61-76.
53. Osawa S, Kamiya H, Tsuzuki K. 1998. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54: 581-618.
54. Palmer AM, Procter AW, Stratmann GC, Bowen DM. 1986. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease. Neurosci Lett 66: 199-204.
55. Palmer AM, Steele JE, Stratmann GC, Bowen DM. 1990. The N-methyl-D-aspartate receptor complex in Alzheimer's disease: Reduced regulation by glycine but not zinc. Brain Res 500: 369-373.
56. Pearson RCA, Esiri MM, Hiorns RW, Wilcock GK, Powell TPS. 1985. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer's disease. Proc Natl Acad Sci USA 82: 4531-4534.
57. 2+-permeable AMPA receptors in neurological disorders. Trends Neurosci 20: 464-470.
58. Procter AW, Palmer AM, Francis PT, et al. 1988. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem 50: 790-802.
59. 3H]MK-801 binding in Alzheimer's disease. J Neurochem 53: 698-704.
60. Riedel G, Micheau J. 2001. Function of the hippocampus in memory formation: Desperately seeking resolution. Prog Neuropsychopharmacol Biol Psychiatry 25: 835-853.
61. Scannevin RH, Huganir RL. 2000. Postsynaptic organization and regulation of excitatory synapses. Nat Rev Neurosci 1: 133-141.
62. Small DH, Mok SS, Bornstein JC. 2001. Alzheimer's disease and Abeta toxicity: From top to bottom. Nat Rev Neurosci 2: 595-598.
63. Smith CCT, Bowen DM, Francis PT, Snowden JS, Neary D. 1985. Putative amino acid transmitters in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry 48: 469-471.
64. Smith MA, Perry G, Richey PL, et al. 1996. Oxidative damage in Alzheimer's. Nature 382: 120-121.
65. 3H]-MK-801 binding to the N-methyl-D-aspartate receptor complex in human cortical membranes. Eur J Clin Pharmacol 189: 195-200.
66. Terry RD, Masliah E, Salmon DP, et al. 1991. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
67. Williamson R, Scales T, Clark BR, et al. 2002. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: Involvement of Src family protein kinases. J Neurosci 22: 10-20.
68. Wong TP, Debeir T, Duff K, Cuello AC. 1999. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci 19: 2706-2716.
69. Yasuda RP, Ikonomovic MD, Sheffield R, Rubin RT, Wolfe BB, Armstrong DM. 1995. Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: A biochemical study. Brain Res 678: 161-167.